Antibodies targeting tumor antigens (anti-BAFF-R, anti-CD123, anti-CD157, anti-SLAMF7, anti-GD2, anti-CD33) with an enhanced affinity toward CD16, which further increases ADCC efficacy, were evaluated in multiple clinical trials [185]. The gene discussed is CD33; the disease is neoplasm.